Professor Richard A. Yost, PhD

Colonel Allen R. and Margaret G. Crow Professor, Department of Chemistry, University of Florida

The Triple Quadrupole: Innovation, Serendipity and Persistence

Mark Rose, PhD

Director of Drug Metabolism and Pharmacokinetics, CHDI Foundation

The Role of Non-Profits in Drug Discovery and Development

Professor Rigoberto Hernandez, PhD

Gompf Family Professor of Chemistry, Department of Chemistry, Johns Hopkins University

Value of Diversity, Inclusion and Equity in the Sciences

Professor Jack Uetrecht, MD, PhD

Professor of Pharmacy and Medicine, Canada Research Chair in Adverse Drug Reactions, University of Toronto

Predicting the Unpredictable: How the Innate Immune Response to Drugs Predicts Risk

Jim Glick, PhD, Section Head, Translational and Investigational Labs, PK Sciences, Novartis

Immunogenecity Data and the Regulatory Landscape: Bioanalytical Lessons Learned from a Recent Biological Licensing Application Approval

Jaya Goyal, PhD, Vice President, Bioanalytical, Pharmacology, and Biomarker Development, Wave Life Sciences

Title TBA

Chongwoo Yu, PhD, Master Clinical Pharmacology Reviewer, DCEP, Office of Clinical Pharmacology, OTS/CDER/OMPT/FDA

Importance of Bioanalysis in Drug Development

Sean Kim, PhD, Head, DMPK and Clinical Pharmacology, Blueprint Medicines

Title TBA

Timothy Mack, PhD, Senior Principal Scientist, Celgene

Title TBA

Min Meng, Deputy CEO at Chongqing Denali Medpharma, Co. Ltd

Title TBA

Chandra Prakash, PhD, Senior Research Fellow, Agios Pharmaceuticals

Title TBA

Andrew Rowland, PhD, Associate Professor, Flinders Univeristy and Beat Cancer Research Fellow, Cancer Counsil SA

Exosome Markers for Drug Metabolism Pathways

Bonnie Rup, PhD, Biopharmaceutical Development Expert; Bioanalysis, Immunogenicity, Regulatory, Bonnie Rup Consulting LLC

Title TBA

Jim Shen, PhD, Director, Bioanalytical Science, Technical Outsourcing Management Lead, Bristol-Myers Squibb

Title TBA

Sekhar Surapaneni, PhD, Vice President, Nonclinical Disposition Assessment, Bristol-Myers Squibb

Challenges with Ozanimod Approval

Carmin Syznal, MBA, Scientist II / TA Liaison Neuroscience & Immunology -DMPK Group, AbbVie

Title TBA

Theingi Thway, PhD, Principal Scientist, Amgen

Bioanalysis in Therapeutic Biologics Development: Through the Lens of Industry and US-FDA

Yu Tian, PhD, Director, Drug Metabolism and Pharmacokinetics, AbbVie

Microbiome Mediated Pro-Drug Metabolism and Application in Gut- Restricted Drug Design

Jashvant (Jash) D. Unadkat, PhD, Milo Gibaldi Endowed Professor, Department of Pharmaceutics, School of Pharmacy, University of Washington

Complex DDI and Transporter/Metabolism Interplay: Insights from Extended CL Model

Tianyi Zhang, PhD, Executive Vice President of Frontage Laboratories Inc., and General Manager of Frontage China

Title TBA

Huiyu Zhou, PhD, Director, BioAnalytical Research & Development, Celgene

Title TBA

Joleen T. White, PhD, Bioassay Development Lead at Bill and Melinda Gates Medical Research Institute

Practicing Immunogenicity Risk Assessment on Published PEGylated and Multi-specific Biotherapeutics

Guodong Zhang, PhD, Group Head & Associate Director at Alnylam Pharmaceuticals

Bioanalytical Strategies for RNAi Therapeutic Development